Trial Profile
Retrospective trial of omalizumab for the treatment of patients with chronic idiopathic urticaria
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Mar 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 30 Mar 2016 New trial record
- 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology